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Community-acquired pneumonia (CAP) is the most 
common type of lower respiratory tract infection 
and can be life-threatening, especially among young 
children, the elderly and those with comorbid 
conditions.[1] The most common pathogen associated 
with CAP is Streptococcus pneumoniae.[2] Males generally suffer a 
more severe form of the disease with a higher associated mortality. [3] 
For those with diabetes mellitus, pneumonia is associated with more 
severe presentation, poor prognosis and poor outcomes.[4,5] HIV 
infection is also a major risk factor for pneumonia. 
CAP symptoms are non-specific and patients may present with 
both upper and lower respiratory tract symptoms. There is no rapid, 
simple, accurate and cost-effective method for immediate diagnosis 
of CAP in most patients at presentation. A chest radiograph is 
necessary to establish the diagnosis of CAP and to differentiate it 
from other respiratory illnesses.[6] The decision whether or not to 
admit a patient influences the extent of diagnostic testing as well as 
the choice of empirical antimicrobial treatment. Pharmacokinetics, 
efficacy, safety profile, cost, spectrum of activity and whether or 
not a specific pathogen is identified influence antibiotic treatment 
choice. Several clinical societies worldwide have authored treatment 
guidelines for CAP as a way of standardising chemotherapeutic 
treatment.[7-9]
Methods
Our research was conducted at Witbank Hospital (WH), a 350-bed 
secondary-level hospital in Mpumalanga Province affiliated to the 
University of Pretoria as a satellite facility. Clinical records of patients 
who were treated with ceftriaxone or amoxicillin-clavulanate for 
CAP, as diagnosed by the treating clinician, from January 2010 
to January 2012 were selected and categorised according to the 
antibiotic selected. For each group, every fourth file was selected 
beginning with a random number until a total of 100 were reached. 
This gave a total of 200 randomly selected files with half being treated 
with amoxicillin-clavulanate and the other half with ceftriaxone. 
Patients were of any race, gender and over 13 years of age. 
To establish the determinants of choice of antibiotic, we examined 
the severity of disease, presence of comorbid conditions, previous 
hospital admission/antibiotic exposure, contraindications, ease of 
administration of either drug and its availability, or lack thereof. To 
determine treatment outcomes, we established the number of those 
who: (i) were successfully treated/discharged from hospital; (ii) had 
complications, which might or might not have been directly related 
to the choice of antibiotic; and (iii) died. Successful treatment was 
defined by the resolution of symptoms and by recorded resolution 
of pneumonic changes on chest radiograph and/or improvement 
of inflammatory markers (C-reactive protein and white cell count). 
Death was confirmed by a record in the patient file, as were 
complications related to the drugs.
Treatment costs were determined by ascertaining the direct costs 
of acquisition of the antibiotics. Costs related to (i) the diagnosis 
and treatment of pneumonia; (ii) antibiotic administration; and 
(iii) hospital accommodation were determined by interviewing 
relevant hospital personnel. Costs related to other antibiotics used 
in combination with the study antibiotics were similar as the same 
antibiotic (erythromycin) was used. 
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Background. Community-acquired pneumonia (CAP) is a major cause of death and morbidity worldwide. Treatment is centred on 
antibiotics with ceftriaxone and amoxicillin-clavulanate being some of the most commonly prescribed agents. 
Objective. To compare treatment outcomes and costs in patients receiving either of these two antibiotics at Witbank Hospital (WH). 
Methods. A total of 200 randomly selected adult patient files (100 receiving ceftriaxone and 100 amoxicillin-clavulanate) recording a 
diagnosis of CAP were studied to determine the length of hospital stay, comorbid conditions and treatment outcomes. A descriptive and 
comparable analysis was performed. 
Results. Male gender, higher CURB-65 scores and death were associated with the use of ceftriaxone. Severity of disease and previous 
antibiotic exposure influenced the duration of hospital admission. 
Conclusion. Gender and severity of disease (based on the CURB-65 score) were the determinants of antibiotic choice at WH. Male gender 
increased the likelihood of being treated with ceftriaxone, as did a CURB-65 score of >2. There were no differences in the outcomes of 
CAP patients treated with ceftriaxone compared with those treated with amoxicillin-clavulanate. Irrespective of antibiotic used, gender and 
severity of disease influenced treatment outcomes. Male gender was associated with a higher mortality and longer hospital stay. The average 
duration of stay for both antibiotics was not significantly different. Thus, only level 1 and 2 costs need to be considered when comparing 
the two regimens. On this basis, ceftriaxone was cheaper than amoxicillin-clavulanate.
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This study was approved by the Ethics Committee of the University 
of Pretoria.
Statistical analysis
A descriptive and comparable analysis was performed. Continuous 
variables were analysed using the Mann-Whitney U test. Univariate 
analysis was based on the χ2 test for qualitative variables, while 
Student’s t-test was used for quantitative variables. Non-parametric 
tests were used in the absence of a normal distribution. A logistic 
model was used to adjust for the effect of multiple variables such as 
gender, HIV status and severity of disease. A p-value of <0.05 was 
considered significant.
Results
Results are summarised in Table 1. In addition to the comorbidities 
listed, five patients were receiving amoxicillin-clavulanate, and five 
were receiving ceftriaxone. One patient receiving ceftriaxone had 
unexplained hepatitis, with negative viral studies.
Logistic regression was performed to ascertain whether HIV, 
gender, severity of illness (the CURB-65 score) and previous antibiotic 
exposure were determinants of antibiotic choice (Table 2). Severity of 
pneumonia was assessed using the CURB-65 score, which includes 
fives components: C – confusion; U – urea >7 mmol/l; R – respiratory 
rate >30  breaths/min; B – blood pressure, systolic <90  mmHg or 
diastolic <60  mmHg; and 65 - age >65  years.[10] HIV was not a 
determinant of antibiotic treatment choice (p=0.51). Male gender 
was significantly associated with the use of ceftriaxone (p=0.001). A 
higher CURB-65 score was also significantly associated with the use 
of ceftriaxone (moderate CURB-65 score: p=0.003; severe CURB-
65 score: p=0.002). Previous antibiotic exposure was associated 
with a slightly higher use of ceftriaxone, but this was statistically 
insignificant (p=0.799). 
From multivariate logistic regression, it was established that 
only gender and CURB-65 score were associated with ceftriaxone 
treatment (Table 3). There was also a significant interaction between 
gender and CURB-65 score (p=0.046). 
For death as an outcome, choice of antibiotic, HIV status, gender, 
severity of disease and previous antibiotic exposure were analysed by 
logistic regression. Ceftriaxone showed a significant association with 
death as an outcome (p=0.032). HIV showed no significant influence 
(p=0.459). There was a higher incidence of deaths among males. A 
significant association between the severity of disease and death was 
observed (p=0.029). Previous antibiotic exposure was not associated 
with death (p=0.312).
Treatment with ceftriaxone was associated with a slightly longer 
length of hospital stay than amoxicillin-clavulanate; however, the 
difference was not statistically significant (mean 6.21 v. 5.22 days, 
respectively; p=0.093). The HIV-positive status of patients led to 
a slightly longer hospital stay after treatment with ceftriaxone v. 
amoxicillin-clavulanate; however, this was not statistically significant 
(mean 6.04 v. 4.49 days, respectively; rank-sum p=0.253). There 
was no association between gender and length of stay (rank-sum 
p=0.477). Severity of disease did have an influence on the length 
of stay, with moderate disease leading to an average of 5.04 days 
in hospital and severe disease leading to an average of 7.01 days in 
hospital (rank-sum p=0.015). Previous antibiotic exposure also led to 
a slightly longer hospital stay than no previous exposure (mean 6.97 
v. 5.12 days, respectively; rank-sum p=0.015), which is statistically 
significant.
From multivariate logistic regression analysis, death was associated 
with ceftriaxone, a high CURB-65 score and male gender. When 
controlled for gender, treatment was not significantly associated 
with outcome (p=0.191) while severity of disease was associated with 
outcome (p=0.05). 
Discussion
Determinants and treatment outcomes 
When comparing determinants and outcomes of CAP in the two 
antibiotic groups we found that gender played an important role 
in antibiotic choice, with >80% of males prescribed ceftriaxone. 
Additionally, more males in our study had a more severe form of 
pneumonia, as exemplified by a higher CURB-65 score. This is in 
line with previous studies; male gender is a risk factor for developing 
severe pneumonia with higher mortality.[3] 
Table 1. Demographic data
Ceftriaxone
Amoxicillin-
clavulanate
Patients, N 100 100
Age (years)
Range 15 - 83 14 - 89
Average 45.73 41.37
Median 49 37.5
Gender, n
Male 89 46
Female 11 54
Length of hospital  
stay (days)
Average 6.22 5.18
Median 5 5
Patients with previous 
antibiotic exposure, n
34 32
CURB-65 score, average 2.4 2.1
Comorbidities, n
HIV 43 39
T2DM 5 2
Epilepsy 1 2
COPD 3 1
Heart failure 2 6
Ischaemic stroke 2 1
Pneumonia-related 
complications, n
Pleural effusion 1 5
Septic shock 0 1
 Deep vein thrombosis 1 1
Lung abscess 2 0
Outcomes, n
Complications 6 7
 Patients successfully 
treated (discharged)
73 88
Deaths 27 12
T2DM = type 2 diabetes mellitus; COPD = chronic obstructive pulmonary disease.
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Severity of disease also played an important 
role in the choice of antibiotic. Patients with 
higher CURB-65 scores were more likely 
to receive ceftriaxone than amoxicillin-
clavulanate. That ceftriaxone was prescribed 
for sicker patients may suggest that doctors 
believe that ceftriaxone is superior to 
amoxicillin-clavulanate. Studies have shown 
the cure rates of ceftriaxone to be 84% 
and that of amoxicillin-clavulanate to be 
76%,[11,12] a fact that might have influenced 
antibiotic choice in CAP treatment by 
clinicians at WH. 
Severity of disease was also associated 
with a longer hospital stay, the link between 
severity of disease and hospital length of 
stay is well documented.[13] However, as Fine 
et al.[14] revealed, and as was subsequently 
confirmed by others,[15] the length of hospital 
stay for treatment of CAP is not solely 
determined by patient-dependent factors 
such as age, severity of disease and the 
presence of comorbid conditions, but is 
rather heterogeneous with great variation 
between hospitals reflecting physician- and 
hospital-specific behaviours. There is no 
reason to believe that this was the case 
in the current study, given the economic 
and capacity challenges under which WH 
operates. 
HIV-positive status proved not to be a 
determinant of antibiotic choice. Notably, 
41% of patients in our study were HIV-
positive, but we found no link between their 
status and choice of antibiotic regimen. 
Prior antibiotic exposure is thought to be 
a major risk factor for antibiotic resistance. [16] 
However, in our study, it was not a 
determinant. This is not surprising because 
based on analysis of published literature 
on CAP resistance, Feldman[17] concluded 
that ‘little evidence suggests that infections 
with resistant pneumococci per se are more 
severe.’
In comparing treatment outcomes, we 
looked at death or cure and also compared 
different variables looking at the length of 
hospital stay. We found that more patients 
receiving ceftriaxone died compared with 
those receiving amoxicillin-clavulanate. This 
is because sicker patients (most of whom 
were male) were prescribed ceftriaxone. 
However, in the multivariate analysis used 
to predict mortality, gender and severity 
of disease were found to be associated 
independently with a higher mortality 
and, after adjusting for their confounding 
effect, there were no statistically significant 
differences between the two antibiotic 
regimens. The ceftriaxone group had a 
longer duration of stay, averaging 6.22 days 
compared with 5.18 days in the amoxicillin-
clavulanate group. This was not statistically 
significant and the length of hospital stay 
may have been related to factors such a 
severity of disease and presence of comorbid 
conditions, rather than choice of antibiotic. 
In our study, HIV did not increase the risk 
of CAP-related death. The influence of HIV 
on CAP treatment outcomes has been the 
subject of several studies. In three of these 
studies, using univariate analyses of clinical 
outcomes of CAP, higher death rates were 
found among the HIV-infected patients.[18-20] 
However, not surprisingly, the higher death 
rates were among patients who were not 
receiving highly active antiretroviral therapy 
(HAART). Bordon et al.[21] conducted a study 
to evaluate the clinical outcomes of CAP 
among hospitalised HIV-infected patients 
and found that HIV did not significantly 
influence overall mortality rates or CAP-
related mortality rates. Even though a higher 
number of HIV-positive patients with 
pneumonia died in our study (20% HIV-
positive v. 16% HIV-negative, irrespective of 
antibiotic choice), this was not statistically 
significant in line with Bordon et al.’s findings. 
With respect to length of hospital stay, 
the influence of HIV was also statistically 
insignificant. Johnson et al.[22] reported a 
longer hospital stay among HIV-infected 
patients. However, the patients studied 
were not receiving HAART. Studies have 
confirmed the link between introducing 
HAART and a reduction in the incidence of 
bacterial pneumonia cases.[23]
Gender influence on death and length of 
stay as outcomes was statistically insignificant. 
Thus, while males are known to be more 
likely to suffer from a severe form of CAP, our 
results, based on a small sample size, suggest 
that they do not necessarily stay longer in 
hospital and that they are not more likely to 
die. This calls for a much larger sample size in 
future studies as these results are at odds with 
previous studies.[3,24] 
Table 2. Determinants of antibiotic choice: Ceftriaxone
Determinant % (n/N cases) Crude OR 95% CI p-value
HIV
Positive 52.4 (43/82) 1.21 0.688 - 2.125 0.510
Negative 48.3 (57/118) 1.00
Gender
Female 16.9 (11/65) 1.00 3.947 - 16.679 0.001
Male 65.9 (89/135) 8.11
CURB-65 Score
Mild (0 - 1) 5.0 (1/20) 1.00
Moderate (2) 54.0 (60/112) 22.35 2.891 - 172.81 0.003
Severe (3 - 4) 57.4 (39/68) 25.55 3.232 - 201.98 0.002
Previous antibiotic 
exposure
Yes 51.6 (33/64) 1.08 0.596 - 1.959 0.799
No 49.6 (67/135) 1.00
OR = odds ratio; CI = confidence interval.
Table 3. Summary of results
Variables Determinant of choice of antibiotic Outcome Length of hospital stay Treatment cost
HIV Nil association Nil association Longer stay but not 
significant
Nil association
Gender Significant difference Males more affected Nil association Nil association
CURB-65 score Significant difference Significant difference Significant difference Significant difference
Previous antibiotic exposure Association but not significant Nil association Significant difference Significant difference
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Severity of disease (higher CURB-65 score) had a statistically 
significant influence on death as a treatment outcome irrespective 
of antibiotic regimen. The CURB-65 score also had a statistically 
significant influence on the length of hospital stay. These results 
are in line with those from a recent study by Armiñanzas et al.[25] 
However, the mean age in Armiñanzas et al.’s study of 539 patients 
(51% male) was 78 years, which is much higher than in our study. 
The association between death as an outcome and previous 
antibiotic exposure, which could suggest potential resistance, was 
statistically insignificant. There was also no statistically significant 
relationship between the length of hospital stay and previous 
antibiotic exposure. Interestingly, from our results, the group that 
had been previously exposed to antibiotics had fewer deaths although 
a longer hospital stay, giving the impression that previous exposure 
to antibiotics (3 months prior to admission) in CAP is protective 
and reduces the risk of death. For amoxicillin-clavulanate at least, 
this is in agreement with the results from the case-control study by 
Einarsson et al.[26]
Of interest, in our study, we observed that the mean age difference 
(Table 2) was statistically insignificant. Therefore, age as a factor did 
not independently contribute to the choice of antibiotic, or to any of 
the outcomes. 
Complications and comorbid conditions
In addition to the comorbidities listed in Table 1, there was one case 
of prostate cancer, two of underlying fibrotic lung disease, three 
of epilepsy, seven of diabetes, three of stroke and four of chronic 
obstructive pulmonary disease. None of the seven diabetic patients 
in our study (two receiving amoxicillin-clavulanate and five receiving 
ceftriaxone) died and none stayed longer than the median 5 days. 
This is in contrast with a study by Moosa et al.[27] which showed 
an increased risk of mortality and morbidity. Although statistically 
insignificant, with respect to death as an outcome, the results in 
diabetes patients are in line with finding by Belk et al.[28] that, after 
controlling for other variables, patients with type 2 diabetes mellitus 
had a lower risk of in-hospital mortality (but longer length of stay) 
when hospitalised for pneumonia. 
Costs implications
Pharmaco-economic analysis can be classified into three levels 
of costs:[29] (i) level 1 (pharmacy perspective) considers only the 
acquisition price of the study medication; (ii) level 2 adds to the level 
1 costs all other costs directly related to antibiotic use and infection 
treatment – antibiotic-related items include medication preparation, 
dispensing and administration, therapeutic drug monitoring, 
treatment of adverse events and secondary treatment for failures; 
and (iii) level 3 costs include all level 2 items and other hospital costs 
incurred during treatment. The daily cost of occupying a hospital 
bed is highly variable and depends on the type of unit (intensive 
care or general), the levels of technology and services provided, and 
geographic location.
Because the length of hospital stay in both groups showed no 
statistically significant differences, level 3 costs were similar for 
both treatment regimens. With level 2 costs, all other contributors 
were rendered irrelevant by similar treatment outcomes between the 
two antibiotics. In addition, there were no complications related to 
antibiotic use for both regimens. The only relevant aspect under level 
2 costs was the frequency of administration of the antibiotic, with 
amoxicillin-clavulanate, because of its shorter half-life, requiring 
three injections in a 24-hour period while ceftriaxone requires once-
a-day administration. This makes ceftriaxone more cost-effective.
With respect to level 1 costs, ceftriaxone costs R3.40 per vial and 
requires 3.5 ml of sterile water to reconstitute and is given as a daily 
parenteral dose. On the other hand, amoxicillin-clavulanate costs 
R11.80 per vial, requires 20 ml of sterile water for reconstitution and 
is given three times a day. The oral formulations cost R11.88 for 875 
+175 mg (10s) and R11.30 for 250 +125 mg (15s). Thus, ceftriaxone is 
>70% cheaper than amoxicillin-clavulanate over an average treatment 
period of 5 days. The above antibiotic prices are based on the latest 
tender prices at the time of this study.
Conclusion
Gender and severity of disease (CURB-65 score) were determinants 
of antibiotic choice in WH. Male gender predisposed patients to a 
ceftriaxone regimen as does a CURB-65 score of >2. There were no 
differences in the outcomes of CAP patients treated with ceftriaxone 
and those treated with amoxicillin-clavulanate. Irrespective of the 
antibiotic used, gender and severity of disease had an influence 
on treatment outcomes. Male gender was associated with a higher 
mortality and longer hospital stay; however, the average length of stay 
for both antibiotics was not significantly different.
HIV status was neither a determinant of antibiotic choice nor 
had any influence on treatment outcomes. Our study demonstrated 
that there were no differences between the two groups of antibiotics 
and that severity of disease and gender have a large influence on the 
choice of antibiotic. When CAP patients were stratified by HIV status, 
no significant differences existed between the HIV-negative and 
HIV-positive groups. Since length of hospital stay was not different 
in either case, only level 1 and 2 costs needed to be considered when 
comparing the two regimens. On this basis, ceftriaxone is cheaper 
than amoxicillin-clavulanate.
While previous exposure to antibiotics was noted, the specific 
antibiotic was not noted from each patient. Another limitation of the 
study is that even though the HIV status of the subjects was noted, 
whether these patients were receiving HAART or not, the severity 
of the immune-suppression (CD4+ count) and for those receiving 
HAART, the specific combination of drugs they were receiving, were 
not taken into consideration.
For its random nature with respect to patient file selection, there 
were more males in this study than females. All patients in the study 
were recruited from the general medical wards. Cigarette smoking, 
a significant risk factor in the development of pneumonia was 
not studied. Nonetheless, this study provided data on which more 
research can be based to expand the economic impact of treatment 
choice in the management of CAP.
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